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Abstract
Glutamate is the primary excitatory neurotransmitter in the central nervous system
and plays a vital role in the pathology of various disease states. Thus, the manipulation and examination of glutamate has been and continues to be pivotal in experimental research. For example, a chronic administration of phencyclidine (PCP), a
non-competitive glutamatergic N-methyl-D-Aspartate (NMDA) receptor antagonist,
generates behavioral and neurobiological changes that mimic symptoms and microlevel changes found in psychiatric disease states, such as schizophrenia [30]. Prior
research has established that PCP induces cognitive deficits, impedes spatial learning and memory performance, and alters mRNA expression of γ-aminobutyric acid
(GABA)ergic markers parvalbumin, GAD67 , calbindin, and tyrosine kinase ErbB4 in
addition to glutamate NMDA receptor subunits GluN2A and GluN2B in ways that
are comparable to findings in the schizophrenia population [10, 11, 18, 48]. Recently,
a growing interest in observing functional network connectivity (FNC) has lead to
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innovative ways of examining both normal systems and disease states. FNC imaging
has successfully identified similar networks in both humans and rats [29] which has
motivated translational research. Yet, little research has examined the eﬀects of PCP
on FNC in an animal system.
In the current study, we characterized how a sub-chronic administration of PCP
can manipulate FNC and how those changes relate to observed behavioral and mRNA
expression outcomes. Adult male hooded Long Evan rats (N=40) were pre-trained
in the hidden platform Morris water task (MWT) prior to beginning their chronic
treatment. Rats received 14 intraperitoneal (i.p.) injections of either PCP (2.58
mg/kg/injection) or 0.9% saline solution (1 mL/kg) over a period of 26 days. Seventytwo hours after the final injection all animals were anesthetized with isoflurane and
imaged in a 4.7 T Bruker Biospin MRI Scanner. Fast spin-echo anatomical scans,
resting state functional magnetic resonance imaging (fMRI) scans with echo-planar
imaging (EPI) acquisition sequences, and arterial spin labeling (ASL) scans were
acquired during the one-hour imaging session. On day 36, 10 days following the
final injection, a subset of animals (PCP treated n=10, saline treated n=10) were
rescanned to examine the eﬀects of a one week washout period. Following the final
scan all animals were retested in the MWT. The animals were initially tested in 8
retraining trials. After a break of least an hour in their home cage, the animals were
given a short retraining session consisting of 4 trials followed by 8 trials of reversal
where the hidden platform was shifted 180o from the trained location in order to
examine behavioral flexibility. Upon completion of behavioral testing, the animals
were sacrificed and tissue was collected and stored at -80o C for GABA and NMDA
receptor mRNA expression analysis.
Group diﬀerences in the individual components were assessed through comparisons of FNC (inter-component correlations) and spectral power comparisons. Group
independent component analyses (ICA) were conducted through the implementation
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of the Group ICA of fMRI Toolbox (GIFT). Additionally, select brain regions of
interest, including the medial frontal cortex and ventral frontal cortex, were assessed
for mRNA expression. Real-time polymerase chain reaction (RT-PCR) was used to
assess mRNA expression of the GABAergic markers parvalbumin, calbindin, ErbB4,
and GAD67 , as well as NMDA receptor subunits GluN2A and GluN2B. The expression of these receptors within the frontal cortex were compared to expression levels
within the parietal cortex, which was used as a control region. These analyses were
used to observe the neurobiological eﬀects of a sub-chronic exposure to PCP. MWT
data was analyzed to determine the eﬀects of the treatments and to characterize
learning and memory performance changes following a low dose sub-chronic administration of PCP. Finally, these behavioral data also allowed for the examination of
behavioral diﬀerences between groups based on temporal proximity to cessation of
PCP treatment. The PCP exposed animals displayed persistent connectivity changes
and alterations in mRNA expression of parvalbumin, calbindin, and GAD67 .
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Chapter 1
Specific Aims
Changes in glutamatergic function and the transmission of glutamate have been
associated with the pathophysiology of various diseases, such as anxiety disorders,
major depression, bipolar disorder, Alzheimer’s disease, and schizophrenia [24,43,46].
Specifically, one of the predominant theories of schizophrenia is based on findings
that show how blocking N-methyl-D-aspartate (NMDA) type glutamate receptors
produces schizophreia-like symptoms and deficits in both healthy humans and nonhuman mammals [31,37]. This NMDA hypothesis has been the foundation for many
studies that use NMDA antagonists, such as ketamine, MK-801, and phencyclidine
(PCP), to study changes in glutamate, γ-aminobutyric acid (GABA), and NMDA
receptors as well as behavioral changes in possible animal models of schizophrenia.
Manipulations of NMDA receptor function through injections of antagonists [40],
partial antagonists [12], and mutating gene expressions [15] have altered learning and
memory performance and cognitive abilities in various behavioral tasks, including
the Morris Water Task (MWT), novel object recognition, and pre-pulse inhibition
[44]. Additionally, prior research has found that repeated exposure to PCP alters
the neurotransmission of glutamate and leads to the deficits of many GABAergic
markers, such as parvalbumin, calbindin, ErbB4, and GAD67 and alterations to
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glutamate NMDA containing 2A and 2B subunits receptors (GluN2A and GluN2B)
[4, 10, 18, 44].
In recent years, research investigating functional network connectivity (FNC) and
low frequency fluctuations in the blood-oxygen-level- dependent (BOLD) signal measured via functional magnetic resonance imaging (fMRI) have increased in order to
characterize the components and networks in healthy and abnormal systems. Patients with schizophrenia display connectivity diﬀerences within regions of the brain
that have been commonly associated with cognitive deficits found in the disease state,
such as the dorsolateral prefrontal cortex and the temporal lobes [21]. Additionally,
similar components and networks have been identified in human and animal fMRI
analysis, which gives support for further translational work [14, 29]. Yet, the merger
of a sub-chronic PCP model of schizophrenia and measures of FNC research has yet
to be made. This type of research would help establish conditions for which PCP and
the resulting alterations in glutamatergic function is a valid model of schizophrenia.
Toward these goals, two working hypotheses were developed:

A) Chronic administration of PCP will induce similar FNC changes in rats as
those found in the clinical schizophrenia population.

B) The sequelae of PCP exposure that mimic states observed in schizophrenia (a
decrease in mRNA expression of GABAergic markers parvalbumin, calbindin,
ErbB4, and GAD67 and NMDA receptor subunits GluN2A and GluN2B) and
behavioral alterations will be consistent with findings observed in the clinical
schizophrenia population and other models utilize NMDA antagonism.
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1.1

Aims

We propose several experiments organized into two specific aims to address these
hypotheses.

Specific Aim 1 Does chronic exposure to PCP induce persistent changes in FNC
and spectral power in a rodent system?
Experiment Series 1.1 Establish measurements of resting state BOLD signals and
conduct analysis of FNC and power spectra comparisons of components identified using group ICA. Examine if these functional changes are comparable
to changes found in the schizophrenia population and other models involving
NMDA antagonism.

Specific Aim 2 Are changes in mRNA expression for NMDA and GABAergic receptors and behavioral outcomes translational to the clinical schizophrenia population and other established animal models?
Experiment Series 2.1 Determine the eﬀects of PCP on mRNA expression of parvalbumin, calbindin, ErbB4, GAD67 , GluN2A, and GluN2B and determine if
these findings are translational to the clinical population and comparable animal models.
Experiment Series 2.2 Determine the behavioral eﬀects of sub-chronic PCP exposure through the MWT and determine if these eﬀects mimic states observed
in schizophrenia.
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Chapter 2
Introduction
Experimental research with animals has played a vital role in characterizing pathologies and biomechanisms involved in disease states. Through the use of animals,
researchers have been able to explore a breadth of changes within a system that
can help further explain the possible etiologies of various diseases. Thus, establishing valid animal models plays a vital role in being able to characterize disease
states compared to a typically developing and functioning system. For example,
animal research has been pivotal in determining the neurobiomechanisms involved
in schizophrenia. Schizophrenia is a serious psychopathology that aﬀects 1% of the
population. Schizophrenia is comprised of positive symptoms, negative symptoms,
and cognitive deficits that usually arise during early adulthood, primarily around
18-25 years of age. More specifically, schizophrenia patients experience hallucinations and delusions (positive symptoms), sensorimotor gating deficits, auditory and
visual context-dependent processing deficits, emotional processing deficits, and memory impairments (negative symptoms) in addition to information processing, working
memory, and executive functioning disruptions and deficits (cognitive deficits) [30].
Schizophrenia compromises the health and well-being of those aﬄicted with this
life-long disease and the etiology and pathophysiology are still unknown. Current
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pharmacological treatments are centered around the blocking of dopamine D2 receptors through the administration of atypical antipsychotics. These treatments tend to
address the psychotic symptoms, but neglect to alleviate one from the core cognitive
dysfunctions [13]. Understanding the mechanisms involved in this disorder is vital
in order to be able to work towards establishing new therapeutic treatments with
higher eﬃcacy for this population.

2.1

Functional Network Connectivity

Examination of FNC has been a growing topic of interest in the more recent years.
Through the use of fMRI, research has been able to determine in vivo low frequency
fluctuations in BOLD signals. This technique is high applicable to clinical research
and diagnoses, has been used to characterize networks during resting-state and cognitive tasks, and is used to determine network changes in various disease states, including autism spectrum disorder, bipolar disorder, and schizophrenia [3]. Investigations
of human patients with schizophrenia have been able to identify network disruptions
that are linked to cognitive deficits. Research has found that schizophrenia patients
have a higher number of errors and longer reaction times during working memory
tasks and display spatially diﬀerent fMRI activation within the dorsolateral prefrontal cortex (DLPFC) in comparison to the healthy individuals [36]. Furthermore,
Potkin et al. (2009) similarly found that schizophrenia subjects display decreased accuracy and longer reaction times during the Sternberg Item Recognition Paradigm, a
working memory task involving diﬀering memory loads. Schizophrenia subjects display significantly diﬀerent activation in the DLPFC than the normal controls, which
is dependent upon memory load [39]. Kim et al. (2009) determined that during an
auditory discrimination task, schizophrenia patients display irregularities in defaultmode networks, many of which were in the DLPFC [34]. Cognitive deficits have
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been explored within the schizophrenia population through various behavioral studies. Hanlon et al. (2006) discovered that patients with schizophrenia are impaired in
the hidden-platform virtual water maze task (VWMT) [28]. These impairments were
evident through diminished time spent in the correct target quadrant during probe
trials and longer search paths in comparison to the normal controls. Garrity et al.
(2007) also found disruptions in local spatial patterns and temporal frequency in the
default mode network during behavioral tasks that required responding to salient
stimuli [21]. Although components and networks can be identified through in vivo
neuroimaging, these studies do not have the ability to identify neurobioloigcal mechanisms responsible for FNC alterations. Research has begun to study rats in vivo
in order to establish translational work that will allow for the investigation of FNC
and related neurobiological manipulations. Hutchinson et al. (2010) have been able
to successfully scan anesthetized rats and analyze resting-state components through
an ICA of whole-brain BOLD signals [29]. They were able to identify 12 independent resting state networks and found these networks to be similar to those found
in humans at rest. Additionally, comparable default mode networks have been identified in rat and human brains [45]. This network includes the orbitofrontal cortex,
cingulate gyrus (rats) or anterior cingulate cortex (humans), hippocampus, and posterior parietal cortex. Successful comparable fMRI scanning in human patients with
schizophrenia and in rodent systems motivates exploration of FNC within an animal
system that mimics schizophrenia-like symptoms.

2.2

N-methyl-D-aspartate (NMDA) Receptors

There are a number of approaches to modeling schizophrenia-like symptoms in animals, which include the use of transgenic animals [26], manipulations via lesions [32],
and through the administration of NMDA antagonists [14,22,31]. Properly function-
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ing neurotransmission through NMDA receptor requires binding of both glutamate
and glycine in addition to partial membrane depolarization, which allows the release
of the magnesium ion block. A lack of depolarization and/or blocking of one or both
of the binding sites prevents the receptor from opening, which can aﬀect the functioning of the entire neuron. Dysfunctional receptors can trigger non-optimal downstream eﬀects, which have the potential to inhibit the entire system’s ability to function properly. Injections of noncompetitive NMDA antagonists induce schizophrenialike symptoms in healthy humans and animal models in addition to exacerbating
symptoms in those who are already diagnosed with schizophrenia [7, 26, 35]. These
findings support the theory that NMDA receptors have a fundamental role in the
neuropathology of schizophrenia and have established a foundation for the NMDA
receptor hypofunction hypothesis. This hypothesis states that the mechanisms responsible for the rise of schizophrenia-like symptoms are dysfunctional NMDA receptors, primarily on GABAergic interneurons. This dysfunction leads to an abundance
of glutamate in the extracellular space causing a lack of excitation of GABAergic interneurons, which leads to a lack of inhibition on groups of various neurons receiving
inputs from the dysfunctional GABAergic interneurons. The absence of inhibition
of groups of neurons can disrupt the overall function of neuronal networks and could
lead to downstream cognitive deficits. Due to the abundant evidence that manipulating NMDA receptors leads to schizophrenia-like symptoms, translational animal
research has often used this as a model to mimic and explore this disease state.
These models involved the administration of NMDA receptor antagonists, such as
MK-801, ketamine, and phencyclidine (PCP). PCP is a noncompetitive NMDA receptor antagonist commonly utilized pharmaceutical drug in modeling schizophrenia.
PCP blocks the activation of the receptor from within the receptor pore and exposure has been found to have lasting eﬀects. on both presynaptic and postsynaptic
structures [31]. Previous research has shown that chronic exposure to PCP decreases
mRNA expression of GABAergic markers parvalbumin, calbindin, ErbB4 and GAD67
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and alters NMDA receptor subunits GluN2A and GluN2B [1, 4, 10, 11, 18, 48]. These
mRNA expression deficits have been primarily identified in frontal cortex structures
that are key to cognitive function and that have been highly associated with changes
found in schizophrenia [10, 16]. Consistent findings of various markers being altered
after assaulting a system with PCP has motivated researching mRNA expression to
help verify this specific chronic PCP model as a valid model.

2.3

Behavioral Changes

Chronic and sub-chronic administration of PCP in animals also induce several behavioral changes, many of which mimic those found in the schizophrenia population.
Abdul-Monim et al. (2006) found that sub-chronic administration of PCP (2mg/kg)
significantly impeded correct responding during the reversal phase of operant learning [2]. Reversal learning in a spatial discriminant two-lever operant learning task
was also disrupted by sub-chronic administrations of PCP at a dose of 1 mg/kg and
2 mg/kg [17]. Deficits in extradimensional set shifting using an attentional set shifting paradigm and sensorimotor gating through pre-pulse inhibition testing have also
been consistently induced through the use of varying dosages of sub-chronic PCP
administration [19,23]. All of these behavioral alterations are analogous to cognitive
deficits commonly found in schizophrenia patients [30].
The MWT is an experimental paradigm that explores learning and memory abilities and is dependent upon NMDA receptor function. Increases in GluN2A protein
expression has been linked to the plasticity of spatial memory and was found to be
pivotal for short term memory processing while GluN2B protein expression has been
positively correlated with long-term memory processing [33]. Inversely, exposure to
NMDA agonists, such as GLYX-13, has shown to promote learning and memory
abilities in animals [12]. Furthermore, enhancement of GluN2B function has been
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shown to enhance long-term memory performance in MWT [8]. Due to the role
of NMDA receptors in learning and memory performance, MWT has been used to
characterize and validate the use of NMDA antagonists in animals. PCP consistently
impairs performance in spatial learning and memory and learning flexibility in the
MWT [6, 26]. Due to the strong association between NMDA receptor manipulation
and behavioral performance in MWT, we chose to use this paradigm to characterize
how our PCP regimen manipulates spatial learning, memory, and behavioral flexibility. This behavioral task can help verify the validity of this PCP model and can assist
in exploring the relationship between these behavioral outcomes and the cognitive
deficits found in the schizophrenia population.

2.4

Innovation

Minimal research has explored the eﬀects of PCP through in vivo scanning. For
example, Gozzi et al. (2008) used pharmacological magnetic resonance imaging
(phMRI) in order to examine the eﬀects of an acute administration of PCP (0.5
mg/kg i.v.) and its interaction with D-serine and SSR504734 [27]. Barnes et al.
(2015) found decreased cortical thickness and gray matter in rats exposed to PCP (5
mg/twice daily for 7 days) [5] yet no research has been undertaken to examine FNC
changes in an animal system that has been manipulated by a low dose, sub-chronic
model of PCP in order to mimic schizophrenia-like symptoms [16, 37]. Our research
aims to characterize resting-state FNC through a sub-chronic, low-dose administration of PCP. We hope to identify components and networks that can be related to
results from human schizophrenia fMRI research. Furthermore, we aim to validate
mRNA and behavioral outcomes that are commonly associated with NMDA receptor manipulations and schizophrenia. This type of research could be a large step
in validating animal models, which could be a stepping stone to other innovative

9

Chapter 2. Introduction
techniques in analyzing, diagnosing, and treating disease states that are associated
with NMDA changes.
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Materials and Methods

3.1

Subjects

Forty male hooded Long Evan rats (Charles River Laboratories International, Inc.)
weighing 340-400 grams at the beginning of treatment were housed in the Biomedical Research and Integrative NeuroImaging Center (BRaIN) animal research facility
under a 12h/12h light/dark cycle (lights on at 7:00am). All animals were acclimated
for 2 weeks before the start of the study and were pair-housed with a same-drug
condition cage-mate in standard plastic cages with food and water available ad libitum. All animals were briefly anesthetized with isoflurane and ear notched. Rats
were handled daily for one week prior to the beginning of behavioral testing and the
start of injections. Rats were randomly assigned to the PCP treatment (n=20) or to
the saline vehicle control treatment (n=20). Within the two drug treatment groups
the animals were randomly assigned into 2 equally sized groups, one of which was
scanned only on day 29 and other that was scanned on days 29 and 36 (PCP/scanned
on day 29 only: n=10, saline/scanned on day 29 only: n=10, PCP/scanned on days
29 and 36: n=10, saline/scanned on days 29 and 36: n=10). All animals were treated
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in accordance to the National Institutes of Health Guidelines for the Care and Use
of Laboratory Animals. All experiments were approved by the Institutional Animal
Care and Use Committee of the University of New Mexico Health Sciences Center.

3.2

Drugs

D-phencyclidine hydrochloride (PCP) was obtained from Sigma, dissolved in sterile
Dulbecco’s phosphate buﬀered saline solution (Sigma), and balanced at a pH of 7.
After 1 day of training in the hidden platform MWT, PCP (2.58 mg/kg/injection)
was administered to 20 rats through intraperitoneal (i.p.) injections. Sterile 0.9%
saline solution (1 mL/kg) was administered as a vehicle control to 20 rats through
i.p. injections. All animals received 14 injections over a 26 day period. Injections
were given daily for the initial 5 consecutive days then for three days over each of
the following three weeks. This resulted in rats receiving injections on days 1, 2, 3,
4, 5 (week 1), 8, 10, 12 (week 2), 15, 17, 19 (week 3), 22, 24, and 26 (week 4; see
Figure 3.1).

Figure 3.1: Timeline of sub-chronic sub-intermittent treatment of PCP or saline,
fMRI scanning, behavioral testing, and tissue collection.
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3.3
3.3.1

Behavioral Testing
Hidden Platform Morris Water Task (MWT)

A blue circular pool (74 cm deep, 175 cm diameter) was placed in the middle of the
testing area and filled with water to a depth of ∼28 cm. The water was approximately

21-23o C and was made opaque by the addition of nontoxic powered white paint. The
pool was surrounded by two white-painted brick walls on the north and west sides
and two gray fabric walls on the south and east side created by a portable partition
(200 cm high, 500 cm wide). The platform (27 cm high, 16 cm wide, 16 cm length)
was made of white PVC pipe and similar white materials. The top of the platform
was covered in a metal wire grid to allow the animals to get on it with ease. It was
placed in the pool in the middle of the north or south quadrant and was submerged
under ∼1 cm of water. Diﬀerent complex cues were hung on the walls nearby the
northwest and south locations and a simple cue was located by the east. Additionally,
there was a paper towel dispenser at the west location and a large gap between the
white brick wall and the gray partition that may have served as distal cues for the
animals. Behavior was recorded by an overhead camera which was attached to a
video recording system. Videos were imported and digitized in order to track and
analyze the animal’s behaviors.

Pre-injection Training
All animals were ran through a total of 16 training trials and one probe trial the
day before starting injections. This was done in order to establish a baseline of
behavior before being introduced to any type of treatment or scanning. Pre-training
allows for the comparison of how the animal behaved initially to how the animal
behaved after receiving their treatment. Furthermore, allowing for a pre-training
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period helps verify that any behavioral changes seen after the injection regiment are
attributable to the treatment and helps eliminate the possible eﬀects of non-specific
learning deficits (e.g. initially learning how to swim, learning that there is a platform,
learning not to engage in thigmotaxic search, and learning to search the open area).
The platform was hidden 37 cm from the pool wall in the center of the north or
south quadrant. Half of the animals were trained with the platform in the north
quadrant and the other half in the south quadrant in order to account for possible
location bias. Each animal was trained for four blocks consisting of four trials per
block (total of 16 trials). In each of the blocks, the rat was released once in each of
the equally spaced intermediate cardinal directions (northwest, northeast, southwest,
and southeast) around the perimeter of the pool. The sequence of the release points
was randomized within and between blocks. Once the animal was released, it had 60
seconds to find the hidden platform. The experimenter tracked the latency from the
time the animal was released to the time that the animal’s front paws touched the
platform. If the animal did not find the platform within the allotted time, it would be
guided to the platform by the experimenter and allowed to observe the surroundings
for a few seconds before being brought back to its holding cage. Animals were tested
in groups of three and were towel-dried in front of a heater after the first block and
after the third block to help alleviate any possibility of hypothermia or exhaustion.
After the completion of the training trials, the rats were tested in one no-platform
probe trial. For the probe trial, the platform was removed from the pool and the
animals were released in a novel location, either west or east. The rats were allowed
to swim for 45 seconds before being removed from the pool and placed back in its
holding cage. Searching behaviors were analyzed during this trial by examining how
long they spent in the hidden platform quadrant and how many times they crossed
the spot corresponding to the trained platform location. All trials were taped via an
overhead camera. Video was digitized and transferred to a Mac workstation for the
use of tracking software developed in our laboratory. The coordinates obtained from
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the tracking software were used to obtain the dependent measures of interest, such
as latency and swim path length to reach the platform location.

Post-scan Testing
On the day following the final scan, all animals were retested in the MWT. The
post-scan test consisted of 1 probe trial, 8 retraining trials, a break of at least one
hour, 4 retraining trials and 8 reversal trials. In the initial no-platform probe trial,
each animal was released in the same novel location, either east or west, as they
were released in the pre-treatment probe trial. The animals were allowed to swim
for 45 seconds, removed from the pool by the experimenter, and placed back in their
home cage. The platform was placed in the original training location, either north
or south, and the animals were retrained for 2 blocks (4 trials per block). Again,
each block consisted of the rat being released once in each of the equally spaced
intermediate cardinal directions (northwest, northeast, southwest, and southeast)
around the perimeter of the pool. The sequence of the release points was randomized
within and between blocks. Just as in pre-training, once the animal was released it
had 60 seconds to find the hidden platform. The experimenter tracked the latency
from the time the animal was released to the time that the animal’s front paws
touched the platform. If the animal did not find the platform within the allotted
time, it would be guided to the platform by the experimenter and allowed to observe
the surrounding area for a few seconds before being brought back to its holding cage.
After the initial retraining session was complete, the animal was towel-dried in front
of a heater before being placed back in its home cage in the colony room. The animal
was given a break of at least 1 hour in its home cage between the two bouts of testing.
The second half of testing examined the flexibility of the learning within the diﬀerent
treatment and scan time groups. Rats were given 1 block of 4 trials of retraining
where the platform was in the original training location. Following this retraining
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session, rats were tested in a reversal paradigm where the platform was moved to the
opposite location in the pool. If the animals were trained with the platform in the
north quadrant, the platform was moved to the south quadrant and vice versa. Rats
were then released in one of the four intermediate cardinal locations and allowed to
search for the platform for 60 seconds, just as in the retraining trials. Testing and
latency recordings were conducted and tracked in the same manner described in the
retraining section above. After the animals completed the reversal sessions, the rats
were sacrificed and tissue was collected for mRNA expression analysis.

3.4

fMRI Scanning

On day 29, three days after the completion of the sub-chronic treatment administration, all animals (weighing 392-559g at the time of scanning, mean weight = 445.64g)
were scanned in the 4.7T Bruker Biospin MRI Scanner (BRaIN MR Imaging Core).
Additionally, a subset of animals (weighing 400-542g at the time of scanning, mean
weight = 469.65g) were rescanned on day 36, allowing for a washout period of 7 days
from the initial scan time point. In preparation for imaging animals were individually,
rapidly anesthetized with isoflurane, placed in the animal holder/MRI probe apparatus, and positioned inside the magnet with the head stabilized in a fixed location
within the imaging coil. Anesthesia was maintained with 2.5% isoflurane carried by
O2 (1L/minute) through a close fitting snout mask. Body temperature, respiration
rate, CO2 , and O2 levels were continuously monitored and recorded throughout the
scanning sessions. RARE-8 T1 image sequences were collected for co-registration
with the following parameters: slice thickness=1mm, TE=56ms, flip angle=180o ,
FOV=3.84x3.84 cm2 , matrix=256x256. The anatomical scan included shimming
and allowed for the isoflurane concentration and global hemodynamics to stabilize
prior to acquiring fMRI images. Resting state fMRI BOLD data were collected
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after the anatomical scan with an echo-planar imaging (EPI) acquisition sequence
with the following parameters: 26 1 mm slices, TR=2s, TE=21ms, flip angle=90o ,
FOV=3.84x3.84 cm2 , matrix=64x64. Finally, arterial spin labeling (ASL) image
data were collected to address blood perfusion with the following parameters: 1 mm
slices, 44 averages, TR=16s, TE=45.99ms, flip angle=180o , FOV=3.84x3.84 cm2 ,
matrix=128x128.

3.5

Quantitative Real-Time PCR (qRT-PCR)

Upon the completion of the Morris water task post-scan session, rats were anesthetized using isoflurane and decapitated. Tissue punches from the medial frontal
cortex, ventral frontal cortex, M1/M2 region, and the parietal cortex in addition to
the whole cerebellum and bilateral hippocampi were extracted and placed into individual 1.5mL RNAse-free tubes. The tissue samples were frozen on dry ice and stored
at -80o C. qRT-PCR analysis were conducted as described previously in Bullock et
al. (2008) and Bullock et al. (2009) [10,11]. Tissue samples were homogenized using
a Polytron homogenizer (Brinkmann Instruments, Inc.; Westbury, NY). Total RNA
was isolated using an RNeasy mini kit (Qiagen). cDNA was synthesized from a portion of the total RNA using Superscript II reverse transcriptase (Life Technologies) in
accordance with the manufacturer’s protocol. Exon spanning primer pairs specific to
GABAergic markers parvalbumin, calbindin, ErbB4, and GAD67 and NMDA receptor subunits GluN2A and GluN2B were designed by using Primer Express 3.0 (Life
Technologies) and validated through the use of NCBI primerBLAST software. All
RT-PCR reactions were ran in an Applied Biosystems 7000 machine. Gene expression
R Green (Life Technologies).
levels for all tissue samples were measured using SYBR�

Expression levels for the genes of interest were normalized against those of β-actin.
Primer dimerization were examined by dissociation curve analyses.
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3.6

Analysis

All image preprocessing was conducted in SPM8 (www.fil.ion.ucl.ac.uk/spm). EPI
image sequences were realigned, spatially normalized to a template brain [42] corresponding to the atlas of Paxinos and Watson with a final voxel size of 0.2mm3 ,
and smoothed (0.8mm kernel). FNC data were assessed using a group (ICA) approach through the implementation of the Group ICA of fMRI Toolbox (GIFT,
http://mialab.mrn.org/software/gift/index.html). We determined the between component correlation coeﬃcients for each animal, estimated 40 components, and excluded artifactual components based on visual inspection. Group-wise diﬀerences
were analyzed in component spectra and functional connectivity (cross-correlations).
Expression of mRNA for parvalbumin, calbindin, ErbB4, GAD67 , NR2A, and NR2B
were normalized against expressions of β-actin using 2−∆∆C T method [41]. Primer
dimerization were examined by dissociation curve analyses. Latencies and path
lengths for each training trial were quantified for each rat. Diﬀerent repeated measures analysis of variances (ANOVA) were conducted for the pre- treatment and the
two post-scanning time points. Additionally, an ANOVA was conducted in order to
compare the averaged latencies and path lengths of the re-training block and the
reversal blocks.
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4.1
4.1.1

Functional Network Connectivity (FNC)
Orientation To The Presentation Of The FNC Results

An explanation of the following results section was deemed necessary due to the
high density of the data. This section of the document has been formed in order
to orient the reader to the organization of the FNC dataset. The results section
begins by quantitatively and qualitatively describing the components observed in
this study. These components will be used throughout the rest of the analyses in
order to assess connectivity. An overall FNC matrix collapsed across treatment
groups and time points will be presented. The rest of the connectivity results will
be described according to the associated time that the scan occurred. All data from
day 29 will be described followed by all of the data from day 36. Within each time
point the following organizational tier will be applied. First, there will be qualitative
and quantitative descriptions and figures of the treatment specific (saline and PCP)
FNC matrices. Additionally, descriptions of the qualitative diﬀerences between the
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treatment groups will be described. Statistical analysis (t-tests) on the eﬀects of
the treatment will be presented followed by the details of the significant diﬀerences.
These simple analyses were conducted in order to assess the eﬀect of exposure to
PCP versus saline. Following the results from the individual scan time points, there
will be qualitative and quantitative descriptions of the eﬀect of the one-week wash
out period. The statistical analyses (t-tests) will be presented followed by the details
of the significant diﬀerences. The reader is encouraged to reference figures (4.1-4.10)
while reading the results section in order to gain a comprehensive understanding of
the FNC data.

4.1.2

Components

A total of 21 non-artifactual components were retained from the initial set of 40
components throughout the striatum, thalamus, cortex, hippocampal, midbrain and
cerebellum (see Figure 4.1).
Specifically, three striatal (St1-St3), four hippocampal (H1-H4), ten cortical (Cx1Cx10), one thalamic (T1), one cerebellar (Cb1), and two midbrain (Mb1-Mb2) components were retained for the group component analysis using the FNC toolbox
within the Group ICA of fMRI (GIFT) toolbox. The iq (stability) for these components ranged between 0.91-0.97 with a mean of 0.95. Artifactual components were
excluded based on visual inspection of the spatial location and distribution of the
component. In the figures, the components are labeled according to the brain region associated with the peak and organized anterior to posterior within each brain
region.
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Figure 4.1: Twenty-one non-artifactual components identified and used throughout
functional network connectivity and spectral time course analyses. Component tmap images are composed of sagittal, coronal, and transverse views with a threshold
of 3.7. Components are organized anterior to posterior within brain regions and
based oﬀ of the peak t-value indicated by the yellow coloring.

4.1.3

Overall Functional Network Connectivity

Throughout all analyses relationships were deemed significant at p<0.005 (black
dots) or p<0.00025 (white dots). When collapsing across both treatment groups and
both time points, 154 relationships out of 210 pair-wise comparisons were found to
be significant (see Figure 4.2).
Most relationships were found to be significant at p<0.00025. Specifically, the
154 significant correlations were composed of 129 relationships that were significant
at p<0.00025 and 25 relationships that were significant at p<0.005. All major brain
regions were significantly correlated within and between all other brain regions in
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Figure 4.2: Overall correlations matrix demonstrates which components are significantly diﬀerent than zero when components are collapsed across both treatment
conditions.

some way. There were no regions that completely lacked a significant relationship
with another brain region. Of the 154 significant relationships 72 were positive
correlations and 82 were negative correlations. Positive correlations were identified
in striatal-anterior cortical, posterior striatal-anterior hippocampal, thalamic-midcortical, thalamic-hippocampal, thalamic-midbrain, posterior hippocampal, posterior cortical-midbrain, posterior cortical-cerebellar, posterior hippocampal-midbrain,
posterior hippocampal-cerebellar, and midbrain-cerebellar component relationships.
Negative correlations were identified in striatal-thalamic, striatal-posterior cortical, striatal-posterior hippocampal, striatal-midbrain, striatal-cerebellar, thalamicanterior cortical, thalamic-cerebellar, anterior cortical-midbrain, anterior corticalcerebellar, anterior hippocampal-midbrain, and anterior hippocampal-cerebellar com-
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ponent relationships. Overall, midbrain and cerebellar components tend to follow
the same directional trends and components that occur spatially close to one another tend to be positively correlated and negative correlated to components that
are spatially distant.

4.1.4

FNC on Day 29 - Saline Exposed Animals

All animals received an fMRI scan on day 29, three days after the final injection. At
this time point saline exposed animals displayed a total of 89 significant relationships
out of 210 pair-wise comparisons (see Figure 4.3).

Figure 4.3: Day 29 FNC for saline exposed animals - correlations matrix demonstrates which components are significantly diﬀerent than zero. White dots indicate
significance at p<0.00025. Black dots indicate significance at p<0.005.

A majority of the relationships were significant at p<0.005. Specifically, the
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89 significant correlations were composed of 54 relationships that were significant
at p<0.005 and 35 relationships that were significant at p<0.00025. Of the 89
significant relationships 47 were positive correlations and 42 were negative correlations. Most positive correlations were found in striatal-anterior cortical and
midbrain-cerebellar relationships and scattered throughout cortical-cortical, corticalanterior hippocampal, posterior cortical-midbrain, posterior hippocampal-midbrain,
and posterior hippocampal-cerebellar component relationships. Negative correlations
were primarily found in striatal-posterior hippocampal, striatal-midbrain, striatalcerebellar, anterior cortical-midbrain, anterior cortical-cerebellar, anterior hippocampalmidbrain, and anterior hippocampal-cerebellar and scattered throughout anterior
cortical-posterior cortical, cortical-hippocampal, and within hippocampal component
relationships.

4.1.5

FNC on Day 29 - PCP Exposed Animals

On day 29, PCP exposed animals showed similar trends as the saline exposed animals.
The PCP exposed animals displayed a total of 86 significant relationships (see Figure
4.4).
A majority of the relationships were significant at p<0.005. Specifically, the
86 significant correlations were composed of 56 correlations that were significant at
p<0.005 and 30 correlations that were significant at p<0.00025. Of the 86 significant relationships 46 were positive correlations and 40 were negative correlations.
Most correlations found in the PCP exposed animals followed a similar trend to
those found in the saline exposed animals. The biggest diﬀerences are the decreased
number of significant relationships in the striatal-cerebellar, striatal-hippocampal,
thalamic-hippocampal, thalamic-cortical, and cortical-cortical component correlations. Additionally, there was an increased number of significant correlations in
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Figure 4.4: Day 29 FNC for PCP exposed animals - correlations matrix demonstrates which components are significantly diﬀerent than zero.White dots indicate
significance at p<0.00025. Black dots indicate significance at p<0.005.

the PCP exposed animals in striatal-thalamic, striatal-striatal, cortical-hippocampal,
and cortical-midbrain component relationships.

4.1.6

FNC - Statistical Analysis of Treatment Eﬀects on Day
29

Two-sample t-tests where the saline FNC matrix was subtracted from the PCP FNC
matrix (PCP-Sal) revealed 4 significant diﬀerences between the treatment groups
(see Figure 4.5).
Three of the 4 significant diﬀerences resulted from the PCP animals displaying an
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Figure 4.5: T-test conducted to determine treatment eﬀects occurring on day 29. The
saline data were subtracted from the PCP data (PCP-Sal) in order to determine
the diﬀerences between the treatment groups. Black dots indicate significance at
p<0.005.

increased positive correlation as indicated by the red coloring of the significant boxes.
These occurred in the striatal(3)-cortical(8), cortical(5)-cortical(6), and cortical(4)cortical(10) component relationships. Upon further investigation, these significant
diﬀerences arose from the saline animals displaying negative correlations and the
PCP animals displaying positive correlations in these specific relationships. The
final significant relationship was between the midbrain (2) and the cortex (8). This
negative correlation was driven from the saline group displaying a correlation of 0
and the PCP group displaying a significant negative correlation.
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4.1.7

FNC on Day 36 - Saline Exposed Animals

Half of the animals in each treatment group received an fMRI scan on day 36, ten
days after the final injection. At this time point saline exposed animals displayed a
total of 10 significant relationships, which was a large decrease from the initial 89
significant correlations seen at day 29 (see Figure 4.6).

Figure 4.6: Day 36 FNC for saline exposed animals - correlations matrix demonstrates which components are significantly diﬀerent than zero. White dots indicate
significance at p<0.00025. Black dots indicate significance at p<0.005.

A majority of the relationships were significant at p<0.005. Specifically, nine of
the ten significant correlations were significant at p<0.005. Of the 10 significant relationships 7 were positive correlations and 3 were negative correlations. The positive
correlations were found within striatal, cortical, and hippocampal relationships and
between striatal-cortical and striatal-hippocampal component relationships. Neg-
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ative correlations were found between striatal-hippocampal, cortical-hippocampal,
and cortical-midbrain component relationships.

4.1.8

FNC on Day 36 - PCP Exposed Animals

On day 36, PCP exposed animals showed an increased number of significant relationships compared to the saline exposed animals. The PCP exposed animals displayed
a total of 40 significant relationships (see Figure 4.7).

Figure 4.7: Day 36 FNC for PCP exposed animals - correlations matrix demonstrates which components are significantly diﬀerent than zero. White dots indicate
significance at p<0.00025. Black dots indicate significance at p<0.005.

All 40 of the relationships were significant at p<0.005. Of the 40 significant relationships 24 were positive correlations and 16 were negative correlations. Most of the
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significant trends found in the saline exposed animals were also found in the PCP
exposed animals. The was an increase in positive correlations in striatal-cortical,
cortical-cortical, thalamic-hippocampal, cortical-hippocampal, midbrain-cerebellar,
hippocampal-midbrain, cortical-midbrain, and cortical-cerebellar component relationships in the PCP exposed animals compared to the saline exposed animals.
The PCP exposed animals also displayed an increase in negative relationships in
thalamic-cortical, cortical-cortical, striatal-hippocampal, striatal-midbrain, corticalhippocampal, cortical-midbrain, cortical-cerebellar, hippocampal-hippocampal, and
hippocampal-midbrain component relationships.

4.1.9

FNC - Statistical Analysis of Treatment Eﬀects on Day
36

Similar to the data found in the initial scan on day 29, two-sample t-tests where the
saline FNC matrix was subtracted from the PCP FNC matrix (PCP-Sal) revealed 4
significant diﬀerences between the treatment groups (see Figure 4.8).
All 4 of the significant diﬀerences resulted from the PCP animals displaying
an increased negative correlation as indicated by the blue coloring of the significant boxes. These occurred in the striatal(1)-striatal(3), striatal(1)-hippocampal(1),
thalamic(1)-hippocampal(2), and cortical(2)-midbrain(2) component relationships.
Upon further investigation, 2 of these significant diﬀerences arose from the saline
animals displaying positive correlations and the PCP animals displaying negative
correlations in the striatal(1)-striatal(3) and thalamic(1)-hippocampal(2) component
relationships. The additional 2 significant relationships, striatal(1)-hippocampal(1)
and cortical(2)-midbrain(2) were driven from the saline group displaying a negative
correlation and the PCP group displaying an increased negative correlation. Unlike
the t-tests conducted at the day 29 time period, the t-tests conducted on day 36 re-
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Figure 4.8: T-test conducted to determine treatment eﬀects occurring on day 36. The
saline data were subtracted from the PCP data (PCP-Sal) in order to determine
the diﬀerences between the treatment groups. Black dots indicate significance at
p<0.005.

sulted in mostly negative t-values (Sal>PCP). The total number of negative t-values
increased and positive t-values decreased on day 36 when compared to day 29.

4.1.10

FNC - Statistical Analysis of the Cessation Period on
Saline Exposed Animals

Two-sample t-tests where the day 36 data were subtracted from the day 29 data
(Day 29-Day 36) revealed 4 significant diﬀerences between the scan time points (see
Figure 4.9).
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Figure 4.9: T-tests conducted to determine the eﬀects of the 1 week washout period
in the saline exposed rats. The data from day 36 were subtracted from the data from
day 29 (Day 29-Day 36) in order to determine the diﬀerences between the two scan
time points. Black dots indicate significance at p<0.005.

Three of the four significant diﬀerences resulted from the data from day 29 displaying an increased negative correlation as indicated by the blue coloring of the
significant boxes (Day 36>Day 29). These occurred in the striatal(3)-cortical(8),
cortical(5)-cortical(6), and cortical(4)-cortical(10) component relationships. Upon
further investigation, the significant diﬀerences between striatal(3)-cortical(8) and
cortical(5)-cortical(6) component relationships arose from the day 29 correlation being around 0 and the day 36 correlation being negative. The additional negative
t-value found in the cortical(4)-cortical(10) component relationship was driven by
the day 29 data being more negative than the day 36 data. The final significant relationship was between the midbrain (2) and the cortex (8). This positive correlation
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was driven from the day 29 data displaying a positive correlation and the day 36
data displaying a negative correlation.

4.1.11

FNC - Statistical Analysis of the Cessation Period on
PCP Exposed Animals

Again, two-sample t-tests where the day 36 data were subtracted from the day 29
data (Day 29-Day 36) revealed 4 significant diﬀerences between the scan time points
(see Figure 4.10).

Figure 4.10: T-tests conducted to determine the eﬀects of the 1 week washout period
in the PCP exposed rats. The data from day 36 were subtracted from the data from
day 29 (Day 29-Day 36) in order to determine the diﬀerences between the two scan
time points. Black dots indicate significance at p<0.005.

Three of the four significant diﬀerences resulted from the data from day 29 dis-
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playing an increased positive correlation as indicated by the yellow coloring of the
significant boxes (Day 29>Day 36). These occurred in the midbrain(2)-cortical(8),
cortical(5)-cortical(6), and cortical(4)-cortical(10) component relationships. Furthermore, the significant diﬀerence between the midbrain(2) and the cortical(8) component was driven from the day 29 correlation being negative and the day 36 correlation being a stronger negative correlation. The cortical(4)-cortical(10) component
relationship was driven by the day 29 data being positive and the day 36 data
being approximately 0. The final positive significant relationship was between the
cortical(5)-cortical(6) components. This positive correlation was driven from the day
29 data displaying a stronger positive correlation than the day 36 data. Inversely, the
fourth significant diﬀerence that occurred between the striatal(3)-cortical(8) components was negative and arose from the day 36 data displaying a stronger positive
correlation than the day 29 data.

4.2
4.2.1

Spectral Power Analyses
Orientation To The Presentation Of The Spectral Results

An explanation of the following results section was also deemed necessary due to
the high density of the data and has been formed in order to orient the reader to
the organization of the spectral dataset. In regards to the figures, the components
listed above the FNC section are ordered along the Y axis and the spectral bins
are ordered along the X axis. The spectral data are organized into 0.04 Hz bins for
purposes of simplicity. The data begins with the presentation of two-way analysis
of variance (ANOVA) results that investigate significant interactions, main eﬀects
of treatment, and main eﬀects of time point. Next, t-tests for the overall treatment
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eﬀect (PCP-Sal) and the overall eﬀect of the cessation period (Day 29-Day 36) will
be described. Additionally, t-tests assessing the treatment eﬀects on the day 29 and
day 36 will be presented. The reader is encouraged to reference Figures 4.11-4.13
while reading the results section in order to gain a comprehensive understanding of
the spectral power data.

4.2.2

Spectral Power - ANOVA Interactions

A total of 4 significant interactions (treatment X time) were observed (see Figure 4.11
A). The midbrain component 1 was significant (Sal>PCP, Day 29>Day 36) in the
0.20-0.24 Hz range at p<0.05. The additional significant interactions were identified
in the hippocampus. Hippocampal components 1 and 2 were significant in the 0.160.20 Hz range at p<0.05. Significance in hippocampal component 1 was driven by
Sal>PCP and Day 36>Day 29 while significance in hippocampal component 2 was
driven by Sal<PCP and Day 29<Day 36. Additionally, hippocampal component
3 was significant in the 0.08-0.12 Hz range at p<0.05/6. This result was due to
Sal>PCP and Day 36>Day 29. The details of the results and further t-tests were
conducted below.

4.2.3

Spectral Power - ANOVA Treatment Main Eﬀect

ANOVAs yielded a total of 19 significant treatment main eﬀects throughout the
components (see Figure 4.11 B). These main eﬀects were comprised of 12 eﬀects that
were significant at p<0.05 and 7 eﬀects that were significant at p<0.05/6. Most of the
A total of 7 eﬀects were significant in the 0.00-0.04 Hz frequency range and were found
in the midbrain (2), hippocampus (2, 3, and 4), cortex (2 and 5), and the striatum
(2). Cortical component 3 was significant at 0.08-0.12 Hz, cortical component 4 and
hippocampal component 3 were significant at 0.12-0.16 Hz, and cortical component
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5 was significant at 0.16-0.20 Hz. Finally, 8 treatment main eﬀects were significant
at 0.20-0.24 Hz and were found in the cerebellum (1), hippocampus (2), cortex (1, 2,
4, and 5), thalamus (1), and the striatum (1). The details and further t-tests were
conducted below.

4.2.4

Spectral Power - ANOVA Time Point Main Eﬀect

ANOVAs resulted in 2 significant main eﬀects (p<0.05) of the time point (see Figure
4.11 C). These main eﬀects occurred in the striatum (3) and the midbrain (2). The
striatum component was significant in the 0.16-0.20 Hz frequency range and the
midbrain component was significant in the lowest frequency range of 0.00-0.04 Hz.
Both striatum and midbrain significances were driven by Day 36>Day 29. Additional
t-tests and details are described below.

4.2.5

Spectral Power - Statistical Analyses of Treatment Effects

Two-sample t-tests were conducted on all of the scans in order to determine the eﬀects
of the treatment on spectral power (see Figure 4.12A). These analyses were collapsed
across scan time points and were conducted by subtracting all of the saline data from
the PCP data (PCP-Sal). Overall, all of the components consistently displayed a
stronger power in the PCP exposed animals (PCP>Sal) for the highest frequency
bin of 0.20-0.24 Hz. As the power decreases, the t-values become more negative for
almost all of the components. This results in the lowest frequency bins (0.00-0.04,
0.04-0.08, and 0.08-0.12) being comprised primarily of greater power in the saline
exposed animals (Sal>PCP). Specifically, the treatment analysis resulted in a total
of 17 significant diﬀerences (p<0.05 or p<0.05/6), 9 positive and 8 negative results.
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Figure 4.11: ANOVA omnibus p-value maps conducted on spectral power. The separate figures indicate significant (A) interactions, (B) the main eﬀects of treatment,
and (C) the main eﬀects of the time point. Red dots indicate significance at p<0.05
and blue dots indicate significance at p<0.05/6.

PCP exposed animals displayed greater power in seven out of nine significant results
(PCP>Sal). These eﬀects occurred in the 0.20-0.24 Hz frequency and incorporated
the striatum (1), thalamic (1), cortical (1, 5, and 7), hippocampal (3) and cerebellar
(1) components. The PCP rats had significantly greater power in cortical component
5 at 0.16-0.20 Hz and in cortical component 4 at 0.12-0.16 Hz. The saline exposed
animals displayed greater power (Sal>PCP) in 2 components at 0.12-0.16 Hz, 1
component at 0.08-0.012 Hz, and 5 components at 0.00-0.04 Hz. The significant
eﬀects at the 0.12-0.16 Hz frequency occurred in the cortical (1) and hippocampal
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(3) components. The significant diﬀerence at 0.08-0.12 Hz occurred in the cortical 3
component. The majority of the eﬀects occurred at 0.00-0.04 Hz and were identified
in the striatal (2), cortical (2 and 5), hippocampal (4), and midbrain (2) components.

4.2.6

Spectral Power - Statistical Analysis of Cessation Period Eﬀects

An examination of the cessation period was completed through two-sample t-tests,
which were conduct on all of the animals that received 2 scans (n=20) regardless of
treatment in order to determine the eﬀects of the 1 week cessation period on spectral
power (see Figure 4.12B). These analyses were collapsed across treatment and were
conducted by subtracting all of the day 36 data from the day 29 data (Day 29-Day
36). There was a mix of increases (Day 29>Day 36) and decreases (Day 36>Day
29) in spectral power trending throughout the entire analysis, but, similarly to the
treatment eﬀect, there was a trend towards greater power in the Day 29 data in the
highest frequency bin, 0.20-0.24 Hz and a trend towards greater power in the Day 36
data in the lower frequency bins, 0.00-0.04 and 0.04-0.08 Hz. Specifically, the time
point analysis resulted in 1 significant diﬀerence (p<0.05). This significant result
found in the midbrain (2) was due to the Day 36 data having greater power (Day
36>Day 29) and occurred in the lowest frequency bin, 0.00-0.04 Hz.

4.2.7

Spectral Power - Statistical Analyses of Treatment Effects on Day 29

An examination of the eﬀects of treatment on spectral power was conducted on the
entire group of scans from the day 29 time point (see Figure 4.13A). These analyses
address the treatment eﬀects that occurred 3 days following the final injection. The
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Figure 4.12: T-tests conducted to determine the eﬀects of the treatment (A. PCP-Sal)
and the 1 week washout period (B. Day 29-Day36). Black dots indicate significance
at p<0.05 and white dots indicate significance at p<0.05/6.

results were completed by subtracting the saline data from the PCP data (PCP-Sal).
Similarly to the data investigating time eﬀects, there was a mix of positive and negative trends throughout the results. Again, there was a high prevalence of there being
greater power in the PCP rats (PCP>Sal) in the highest frequency bin (0.20-0.24)
and there being greater power in the saline rats (Sal>PCP) in the two lowest frequency bins (0.00-0.04 and 0.04-0.08). The treatment analysis on day 29 resulted in
a total of 5 significant diﬀerences (p<0.05). Four out of the five significant results
were due to an increase in spectral power in the PCP exposed animals compared to
the saline exposed animals. Three of the increases occurred in the 0.16-0.20 Hz fre-
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quency bin and occurred in the striatum (1) and the cortical (5 and 10) components.
Additionally, cortical component 4 was significantly increased at the 0.12-0.16 Hz
frequency. The significant decrease (PCP>Sal) occurred in striatal component 3 at
0.12-0.16 Hz.

4.2.8

Spectral Power - Statistical Analysis of Treatment Effects on Day 36

An investigation of the eﬀects of treatment on spectral power was conducted on the
data from the day 36 time point (see Figure 4.13B). These analyses investigate the
eﬀects of the treatment occur 10 days following the final injection. Again, the results were completed by subtracting the saline data from the PCP data (PCP-Sal).
Trends throughout the day 36 results look similar to the results identified in the overall treatment t-tests (see Figure 4.13A). Overall, all of the components consistently
displayed increases in spectral power for the PCP exposed rats (PCP>Sal) for the
highest frequency bin of 0.20-0.24 Hz. As the frequency decreases the spectral power
also decreases for most of the components. This results in the lowest frequency bins
(0.00-0.04, 0.04-0.08, and 0.08-0.12) being comprised of increased spectral power in
the saline rats (Sal>PCP). These analyses also revealed a total of 23 significant differences, 13 increases and 10 decreases (p<0.05 and p<0.05/6). Twelve out of the
thirteen significant results were due to an increase in spectral power in the PCP exposed animals at 0.20-0.24 Hz. These significant diﬀerences occurred in the thalamic
(1), cortical (1, 2, 4, 5, 6, 7, 8, and 10), hippocampal (3 and 4), and midbrain (1)
components. The remaining increases in power occurred in hippocampal component
1 at 0.04-0.08 Hz. The ten significant increases in spectral power in the saline rats
occurred primarily in the lower frequency bins. Five significant diﬀerences were identified at the 0.00-0.04 Hz frequency were in the thalamic (1), cortical (2, 5, and 6),
and hippocampal (4) components. The hippocampal components 2 and 3 were sig-

39

Chapter 4. Results
nificant at 0.16-0.20 Hz and 0.04-0.08 Hz respectively. The three remaining increases
in the saline rats occurred in the 0.08-0.12 frequency bins and were identified in the
cerebellar component and cortical components 3 and 10.

Figure 4.13: T-tests conducted to determine treatment eﬀects on day 29 (A) and day
36 (B). Black dots indicate significance at p<0.05 and white dots indicate significance
at p<0.05/6.

4.3

Morris Water Task

An alpha of p<0.05 was applied to all analyses and partial eta squared (η p 2 ) are
reported for all significant diﬀerences.
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4.3.1

Pre-injection Training

Prior to the beginning of the injection regiment, all of the rats were pre-tested in the
Morris Water Task (MWT). All animals received 16 hidden platform training trials.
Separate repeated measures analysis of variance (ANOVAs) were conducted on the
path lengths and latencies for all animals and trials (see Figure 4.14). Data were
collapsed across scan time groups within treatment because there were no significant
diﬀerences between the diﬀerent scan time groups.
There was a significant eﬀect of trial for path length (Greenhouse-Geisser corrected F(6.932, 242.635) = 37.769, p<0.001, η p 2 = 0.519) and latency (GreenhouseGeisser corrected F(6.954, 264.241) = 41.048, p<0.001, η p 2 = 0.519). All animals
achieved an asymptote in performance beginning around trial 8 and suﬃciently
learned the task in this training paradigm. There was not a significant trail by treatment interaction in path length (Greenhouse-Geisser corrected F(6.932, 242.635)
= 0.436, p=0.878, η p 2 = 0.012) or latency (Greenhouse-Geisser corrected F(6.954,
264.241) = 0.500, p=0.833, η p 2 = 0.013) throughout the pre-injection training session. This result was expected and supports that any changes seen at the postinjection MWT testing session are due to the eﬀect of the treatment.

4.3.2

Post-Injection Testing

Following the 4 weeks of injections, all of the animals were scanned in the MRI and
half of the animals (N=20; sal=10, PCP=10) received testing in the MWT following
this scan. The remaining half of the animals (N=20; sal=10, PCP=10) experienced a
1-week cessation period before receiving a second scan in the MRI followed by testing
in the MWT. Because the animals were tested in the MWT after the final scan the
data below are grouped into the animals that were tested following the initial scan
on day 29 and the animals that were tested following the second scan on day 36.
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Figure 4.14: Pre-injection MWT training collapsed across scan time groups within
each treatment group. Saline exposed animals are indicated by the open diamonds
and PCP exposed animals are indicated by the closed red squares. The dependent
measures are the length of the swim path (cm, A) and latency (sec, B) to reach the
hidden platform location.

42

Chapter 4. Results
During the testing session, all of the animals were given 8 retraining trials, a break
of at least 1 hour, 4 additional retraining trials, 8 reversal trials, and a no platform
probe.

4.3.3

MWT Retraining Final Scan on Day 29

For the animals that received MWT testing after 1 scan (see Figure 4.15 A and B),
there was a significant eﬀect of trial for path length (Greenhouse-Geisser corrected
F(2.339, 42.099) = 10.959, p<0.001, η p 2 = 0.378) and latency (Greenhouse-Geisser
corrected F(1.993, 35.866) = 15.386, p<0.001, η p 2 = 0.416). All animals achieved an
asymptote in performance beginning on trial 2 and suﬃciently learned the task in
the retraining session. There was not a significant trail by treatment interaction in
path length (Greenhouse-Geisser corrected F(2.339, 42.099) = 0.789, p=0.479, η p 2 =
0.042) or latency (Greenhouse-Geisser corrected F(1.993, 35.866 )= 0.713, p=0.497,
η p 2 = 0.038) throughout the post-injection retraining session. On the first trial of
the retraining session, the PCP exposed animals displayed a non-significant increased
trend in path length and latency to reach the hidden platform. By trial 2, all of the
animals began to behave in a similar manner and their latencies and path lengths
began to asymptote. These data indicate that the animals were proficient in the task
and were taking eﬃcient swim paths to the hidden platform location.

4.3.4

MWT Retraining Final Scan on Day 36

For the animals that received MWT testing after a second scan (see Figure 4.15 C
and D), there was a significant eﬀect of trial for path length (Greenhouse-Geisser
corrected F(2.077, 37.388) = 7.317, p=0.002, η p 2 = 0.289) and latency (GreenhouseGeisser corrected F(1.868, 33.624) = 9.038, p=0.001, η p 2 = 0.334). Similar to the
data from the first set (Day 29) of animals, all of the animals from the second cohort

43

Chapter 4. Results
achieved an asymptote in performance beginning on trial 2. There was not a significant trial by treatment interaction in path length (Greenhouse-Geisser corrected
F(2.077, 37.388) = 0.337, p=0.724, η p 2 = 0.018) or latency (Greenhouse-Geisser corrected F(1.868, 33.624) = 0.272, p=0.748, η p 2 = 0.015) throughout the post-injection
retraining session. Again, on the first trial of the retraining session, the PCP exposed animals displayed a non-significant increased trend in path length and latency
to reach the hidden platform. The data from the second cohort of animals on trial
1 were non-significantly increased compared to the trial 1 data from the first cohort
of animals. By trial 2, all of the two scan animals began to behave in a similar to
that of the animals that received one scan and their latencies and path lengths began
to asymptote. These data indicate that, despite the initial increase in latencies and
path length on trial 1, all of the animals became proficient in the task and were
taking eﬃcient swim paths to the hidden platform location.

4.3.5

MWT Reversal Final Scan on Day 29

The reversal data from the animals that received MWT testing after 1 scan (see
Figure 4.16 A and B) revealed a significant eﬀect of trial for path length (GreenhouseGeisser corrected F(1.931, 34.754) = 16.823, p<0.001, η p 2 = 0.483) and latency
(Greenhouse-Geisser corrected F(1.671, 30.081) = 17.058, p<0.001, η p 2 = 0.487).
Similar to the retraining data, all of the animals began to achieve asymptote in
performance beginning on trial 2. There was not a significant trial by treatment
interaction in path length (Greenhouse-Geisser corrected F(1.931, 34.754) = 0.325,
p=0.717, η p 2 = 0.018) or latency (Greenhouse-Geisser corrected F(1.671, 30.081) =
0.310, p=0.697, η p 2 = 0.017) throughout the post-injection reversal session. Both the
saline and PCP exposed animals displayed an increase in path length and latency in
the initial reversal trial compared to the final retraining trial, which is expected. By
trial 2, all of the animals began to perform in a similar manner and their latencies
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Figure 4.15: Post-injection MWT retraining for both treatment groups (A, B) without and (C, D) with the 1-week cessation period. Saline exposed animals are indicated by the open black and gray diamonds and PCP exposed animals are indicated
by the closed red and pink squares. The dependent measures are the length of the
swim path (cm, A and C) and latency (sec, B and D) to reach the hidden platform
location.

and path lengths began to reach asymptotic levels. These data indicate that all of
the animals, regardless of treatment group, were proficient in the reversal task and
were taking eﬃcient swim paths to the hidden platform location.
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4.3.6

MWT Reversal - Final Scan on Day 36

The data from the animals that received MWT testing after a second scan (see Figure
4.16 C and D) also revealed a significant eﬀect of trial for path length
(Greenhouse-Geisser corrected F(1.951, 35.118) = 17.076, p<0.001, η p 2 = 0.487)
and latency (Greenhouse-Geisser corrected F(1.818, 32.723) = 18.845, p<0.001, η p 2
= 0.511). There was not a significant trial by treatment interaction in path length
(Greenhouse-Geisser corrected F(1.951, 35.118) = 1.196, p=0.314, η p 2 = 0.062) or
latency (Greenhouse-Geisser corrected F(1.818, 32.723) = 1.502, p=0.238, η p 2 =
0.077) throughout the post-injection reversal session. There was an increase in path
length and latency in the saline exposed animals similar to that found in the first
cohort of animals. The PCP exposed animals displayed a non-significant reduced
increase in path length and latency compared to all other groups. By trial 3, all
of the two scan animals began to display an asymptote in a similar manner to that
of the animals that received one scan. Additional measures such as initial heading
trajectory, visits to the old training location, and time spent in the training and
reversal regions were accessed for the reversal trials and the following no-platform
probe trial and no diﬀerences were found between treatment and scan groups (data
not shown).

4.4

Quantitative Real-Time PCR Results

The expressions of 6 genes highly implicated in schizophrenia were analyzed in brain
tissue micro-dissected from the parietal cortex, medial frontal cortex, and ventral
frontal cortex (see 4.17. Expressions of calbindin, GAD67, parvalbumin, ErbB4,
GluN2A, and GluN2B mRNAs were normalized against levels of β-actin, which was
used as a reference because its expression did not significantly vary between treatments or scan time groups.
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Figure 4.16: Post-injection MWT reversal for both treatment groups (A, B) without
and (C, D) with the 1-week cessation period. Saline exposed animals are indicated
by the open black and gray diamonds and PCP exposed animals are indicated by
the closed red and pink squares. The dependent measures are the length of the
swim path (cm, A and C) and latency (sec, B and D) to reach the hidden platform
location.

A significant treatment by time interaction was observed in levels of parvalbumin
expression in the parietal cortex (F = 6.157, df = 1,37, p=0.018) (see Figure 4.18 A).
For the animals that received only 1 scan, the PCP exposed animals displayed an
increased expression of parvalbumin compared to the control animals. Inversely, the
PCP exposed animals that received 2 scans showed decreased expression of parvalbumin compared to the control animals that experienced the same timeline. Within
treatment conditions, the expression of parvalbumin was significantly diﬀerent be-
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Figure 4.17: Summary of analyses investigating treatment main eﬀects, time main
eﬀects, and treatment by scan time interactions in mRNA expression levels of calbindin, GAD67, parvalbumin, ErbB4, GluN2A, and GluN2B in the medial frontal
cortex, ventral frontal cortex, and parietal cortex.

tween animals that received one scan and those that were allowed a cessation period
between the two scans. PCP exposed animals displayed a decreased expression between the two scanning groups while the control animals displayed an increased
expression between groups.
In both scan groups the PCP exposed animals had decreased expression of GAD67
mRNA in the parietal cortex (see Figure 4.18 B) compared to saline exposed control
animals although it was not significant (F = 3.586, df = 1,39, p=0.066).
Additionally, we observed a trend for increased levels of calbindin in the medial
frontal cortex (see Figure 4.18 C) in the PCP exposed animals for both scan groups
when compared to the control animals, but the diﬀerence was not significant (F =
3.461, df = 1,39, p=0.071).
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Figure 4.18: Relative mRNA expression levels of (A) parvalbumin and (B) GAD67
in the parietal cortex and (C) calbindin in the medial frontal cortex.
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Discussion

Repeated exposure to a low dose of PCP resulted in connectivity, spectral power,
mild behavioral, and mRNA expression changes in the rodent system. First, we were
able to successfully identify 21 independent non-artifactual components from the
EPI data and assess resting-state functional network connectivity in rodent systems
exposed to saline and PCP. The present study discovered that sub-chronic subintermittent exposure to PCP results in persistent FNC changes in a rat model.
The treatment eﬀects present on day 29 suggests that PCP alters connectivity with
in cortical regions and between the cortex, striatum, and midbrain. Specifically,
the significant relationships between the cortex and striatum and within cortical
regions are increased in the PCP exposed animals and the relationship between
the cortex and the midbrain was decreased in the PCP exposed animals. There
are also trends for increased correlational strength in the PCP group on day 29
throughout the relationships between the striatum and the hippocampus, midbrain,
and cerebellum. These increases are also found within cortical components, between
cortical-hippocampus components, and between cortical-midbrain components.
In regards to the data that addresses the wash-out period, the PCP exposed
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animals showed an increased number of significant relationships on day 36 compared to the saline exposed animals. These findings suggest that PCP exposure
results in increased hyperconnectivity that is persistent after the wash-out period.
In the PCP exposed rats, there were similar connectivity trends for both day 29 and
36. There were strong positive correlations in the striatal-cortical, hippocampusmidbrain, midbrain-cerebellum, striatal-striatal, and cortical-cortical component relationships. Additionally, there were strong negative correlations in the striatalhippocampal, striatal-midbrain, cortical-hippocampal, cortical-midbrain, and anterior cortical-cerebellar component relationships. These negative correlations were
also present in the relationships between the striatum-thalamic components and
between the anterior hippocampus and the midbrain and the cerebellum. When
comparing the washout period in the saline group and the PCP group there were
several noticeable diﬀerences between the two treatment groups. For example, the
saline exposed displayed trends of negative correlations within the cortical components while the PCP exposed animals displayed an increased number of positive
correlations within the cortical components. Also, when examining the significant
relationships only, the PCP group displayed the inverse of what the saline group
displayed. The significant relationships from the wash-out period were primarily
negative in the saline groups and primarily positive in the PCP exposed group. The
increased correlational strength found in the PCP exposed animals may be indicative of the hyperconnectivity found in the schizophrenia population [20,38,39]. These
changes are likely attributable to the functional consequences of the treatment because there were no structural diﬀerences in overall brain volume. This work is novel
in that it addresses FNC and spectral power changes in a rodent sub-chronically and
sub-intermittently exposed to a low dose of PCP as opposed to the current host of
literature that addresses MRI in exposures to acute and higher doses of PCP [5,9,27].
The persistent eﬀects of the PCP exposure were also present in the spectral
power data. The initial scans on day 29 showed an increased power in the mid to
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high frequency bins (0.12-0.16 and 0.16-0.20 Hz) in the PCP exposed rats. Most of
the significant findings were indicative of the PCP group having a stronger power
compared to the saline group and occurred in the cortex and the anterior striatum
components. There were also trends for decreased power in the lower frequency
bins for the PCP exposed rats. These findings were exacerbated after the washout period. The highest frequency bin (0.20-0.24 Hz) was consistently increased
throughout all of the components in the PCP exposed animals. Most of the lower
frequencies, especially the 0.00-0.04 Hz, had a decreased power for the PCP group.
These outcomes suggest that there is an increased number of persistent changes in
the PCP exposed animals compared to the saline exposed animals.
All of the rats had similar path lengths and latencies in the pre-injection MWT
training session. The initial training session was successful in establishing a consistent
baseline amongst all animals. Because all of the animals performed well in the initial
training session, any changes found in the post-scan testing can be attributed to the
treatment. The animals that received a washout period had increased path lengths
and latencies in trial 1 of the post scan testing compared to the animals that were
tested after the scan on day 29. This change could be due to the additional week
that the animals had to forget the trained platform location. Despite the initial
increased time and path length to find the hidden platform all of the animals from
both time periods reached criterion throughout during the MWT post-scan testing.
The rats that had the additional scan had slightly increased latencies and path
lengths during the first 8 trials of the retraining session, but these diﬀerences were
minimal and non-significant. All animals performed in an almost identical manner
during the retraining session following the hour break. Furthermore, there were
no significant diﬀerences in performance between the treatment groups and scan
time groups during the reversal testing session. The null results throughout the
MWT testing phase indicate that there were not detectable diﬀerences between the
saline and PCP exposed animals in spatial memory or flexible behavior. The lack of
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behavioral diﬀerences in memory could be due to the long time period (4 weeks) in
between the training and testing sessions. The expected eﬀects of PCP on flexible
behavior were not obtained, which may be due to the treatment parameters along
with the possibility that behavioral flexibility in the spatial domain might reflect
compensation by neural systems not aﬀected by PCP.
Some of the changes in mRNA expression are consistent with previously published
results. The decreased expression of parvalbumin and GAD67 in the PCP groups are
consistent with the findings of several animal model and post-mortem clinical studies
[10,11,25]. The initial increase in parvalbumin mRNA in animals that received 1 scan
and the increases in calbindin mRNA in the PCP exposed rats are counterintuitive to
studies that have found decreases in parvalbumin [4, 47, 48] and calbindin [25]. The
inconsistent changes could be due to the fact that the present study was conducted
in adulthood when the expression of these genes are stable and fairly resilient to the
low dose of PCP that was administered.
There are a host of directions and modifications that this study could address
in the future in order to identify additional PCP induced changes. First, additional
analyses could be conducted on the fMRI data. A seed based or graph theory approach could be applied in order to focus in on more specific regions of interest.
Analyses of structural changes in overall gray matter or white matter tracts could
be undertaken to determine if there are structural changes associated with the functional changes found in this study. Second, there could be additional behavioral
tasks incorporated throughout the paradigm. For example, the animals could be
tested in the MWT on a weekly basis in order to avoid the long gap between MWT
sessions. Further, more sensitive behavioral tasks and/or measures could be utilized.
Third, additional qRT-PCR analyses could be conducted in other brain regions, such
as the hippocampus. Expression of other genes associated with schizophrenia could
be measured in the regions that were used in this study and/or in additional tissue.
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Finally, this paradigm could be used in younger animals to determine if these changes
are exacerbated in a developing system. Overall, this study suggests that exposure
to PCP results in connectivity, behavioral, and gene expression changes that are similar to those found in other animal models and the clinical schizophrenia population.
These methods may be used to help diﬀerentiate between PCP and saline exposed
animals and could help identify some underlying mechanisms in schizophrenia.
In summary, we were able to diﬀerentiate the PCP treated rats from the control animals through examination of fMRI and mRNA analyses. We successfully
identified persistent connectivity changes in the PCP exposed rats compared to the
saline exposed rats. Persistent changes were also present in spectral power data.
Although we did not see any behavioral changes in the MWT, the PCP exposed
animals displayed altered mRNA expression levels of parvalbumin, GAD67 , and calbindin. These changes are similar to some aspects of the human schizophrenia and
other animal models that utilize manipulations of NMDARs, but additional research
is needed in order to make this model more indicative of the clinical schizophrenia
population.
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